These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35790417)

  • 1. Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis.
    David MCB; Del Giovane M; Liu KY; Gostick B; Rowe JB; Oboh I; Howard R; Malhotra PA
    J Neurol Neurosurg Psychiatry; 2022 Jul; 93(10):1080-90. PubMed ID: 35790417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline for Alzheimer's disease.
    Birks J; Flicker L
    Cochrane Database Syst Rev; 2003; (1):CD000442. PubMed ID: 12535396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omega-3 fatty acids for the treatment of dementia.
    Burckhardt M; Herke M; Wustmann T; Watzke S; Langer G; Fink A
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009002. PubMed ID: 27063583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological interventions for apathy in Alzheimer's disease.
    Ruthirakuhan MT; Herrmann N; Abraham EH; Chan S; Lanctôt KL
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012197. PubMed ID: 29727467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments.
    Hoang K; Watt H; Golemme M; Perry RJ; Ritchie C; Wilson D; Pickett J; Fox C; Howard R; Malhotra PA
    Trials; 2022 Aug; 23(1):623. PubMed ID: 35915506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of non-invasive brain stimulation on global cognition and neuropsychiatric symptoms in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review.
    Teselink J; Bawa KK; Koo GK; Sankhe K; Liu CS; Rapoport M; Oh P; Marzolini S; Gallagher D; Swardfager W; Herrmann N; Lanctôt KL
    Ageing Res Rev; 2021 Dec; 72():101499. PubMed ID: 34700007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivastigmine for Alzheimer's disease.
    Birks JS; Chong LY; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Sep; 9(9):CD001191. PubMed ID: 26393402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
    Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
    Wang XC; Chu CL; Li HC; Lu K; Liu CJ; Cai YF; Quan SJ; Zhang SJ
    Front Neurol; 2022; 13():1018027. PubMed ID: 36530613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nimodipine for primary degenerative, mixed and vascular dementia.
    López-Arrieta ; Birks J
    Cochrane Database Syst Rev; 2001; (1):CD000147. PubMed ID: 11279679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis.
    Clancy U; Gilmartin D; Jochems ACC; Knox L; Doubal FN; Wardlaw JM
    Lancet Psychiatry; 2021 Mar; 8(3):225-236. PubMed ID: 33539776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of atorvastatin for the treatment of Alzheimer's disease.
    Sun Y; Wang G; Pan Z; Chen S
    Neural Regen Res; 2012 Jun; 7(17):1344-51. PubMed ID: 25657666
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.